Opioid-induced constipation: Challenges and therapeutic opportunities

American Journal of Gastroenterology

Volumn 106, Issue 5, 2011, Pages 835-842

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; IBUPROFEN; LUBIPROSTONE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; NKTR 118; OPIATE; OXYCODONE; PLACEBO; PRUCALOPRIDE; TAPENTADOL; TD 1211; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CHRONIC PAIN; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; HEADACHE; HUMAN; INTESTINE FUNCTION; KNEE PAIN; LOW BACK PAIN; LOW DRUG DOSE; NAUSEA; NONHUMAN; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TOOTH PAIN; TREATMENT RESPONSE; VOMITING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; CONSTIPATION; HUMANS; NALOXONE; PAIN; PHENOLS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU;

EID: 79955578050     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.30     Document Type: Review

References (76)

1. Verhaak PF, Kerssens JJ, Dekker J et al. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain 1998; 77: 231-9. (Pubitemid 28451511)
2. Blyth FM, March LM, Brnabic AJ et al. Chronic pain in Australia: a prevalence study. Pain 2001; 89: 127-134. (Pubitemid 32146391)
3. Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
4. Chou R, Fanciullo GJ, Fine PG et al. and the American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130.
5. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162. (Pubitemid 351222155)
6. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672. (Pubitemid 41395058)
7. Cone EJ, Fant RV, Rohay JM et al. Oxycodone involvement in drug abuse deaths. J Anal Toxicol 2003; 27: 57-67.
8. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Treatment Episode Data Set (TEDS), 1995-2005. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-37. (DHHS Publication No. [SMA] 07-4234) Rockville, MD, SAMHSA, 2007).
9. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and non-medical use of opioids. Pain Physician 2008; 11: S63-89.
10. US Drug Enforcement Administration Automation of Reports and Consolidated Orders System (ARCOS); ( www.deadiversion.usdoj.gov/arcos/retail-drug-summary/ index.html ).
11. Trescot AM, Helm S, Hansen H et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008; 11 (2 Suppl): S5-S62. (Pubitemid 351682078)
12. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1985.
13. Dunn KM, Saunders KW, Rutter CM et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92.
14. Kalso E, Edwards JE, Moore A et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-380. (Pubitemid 39550738)
15. Papagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg 2001; 182 (November Suppl): S11-8.
16. Benyamin R, Trescot AM, Datta S et al. Opioid complications and side effects. Pain Physician 2008; 11 (2 Suppl): S105-20. (Pubitemid 351682081)
17. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A Suppl): 11S-8S. (Pubitemid 34072942)
18. Tuteja AK, Biskupiak J, Stoddard GJ et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430.
19. Bell TJ, Panchal SJ, Miaskowski C et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10: 35-42.
20. Rang HP, Dale MM, Ritter JM. Analgesic drugs. Pharmacology 1999; 13: 579-603.
21. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-671. (Pubitemid 36408072)
22. Stefano GB, Goumon Y, Casares F et al. Endogenous morphine. Trends Neurosci 2000; 23: 436-442.
23. Bagnol D, Mansour A, Akil H et al. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 1997; 81: 579-591. (Pubitemid 27382009)
24. McKay JS, Linaker BD, Turnberg LA. Influence of opiates on ion transport across rabbit ileal mucosa. Gastroenterology 1981; 80: 279-284. (Pubitemid 11217520)
25. Fickel J, Bagnol D, Watson SJ et al. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res 1997; 46: 1-8. (Pubitemid 27214349)
26. De Schepper HU, Cremonini F, Park MI et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 383-394. (Pubitemid 39140632)
27. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl 2): 17-28. (Pubitemid 39468863)
28. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-671. (Pubitemid 36408072)
29. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 103-115. (Pubitemid 26111425)
30. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010; 14: 781-3.
31. Bee LA, Bannister K, Rahman W et al. Mu-opioid and noradrenergic (2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011; 152: 131-9.
32. Chial HJ, Camilleri M, Ferber I et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003; 1: 211-8. (Pubitemid 37248072)
33. Viramontes BE, Malcolm A, Camilleri M et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastroint Liver Physiol 2001; 281: G1468-76.
34. Camilleri M, Busciglio I, Carlson P et al. Pharmacogenetics of low dose clonidine in irritable bowel syndrome. Neurogastroenterol Motil 2009; 21: 399-410.
35. Camilleri M, Kim DY, McKinzie S et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 111-121. (Pubitemid 37248082)
36. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic noncancer pain: tapentadol, a step toward a solution? Curr Med Res Opin 2010; 26: 1677-1684.
37. Hersh EV, Golubic S, Moore PA. Analgesic update: tapentadol hydrochloride. Compend Contin Educ Dent 2010; 31: 594-9.
38. Afilalo M, Etropolski MS, Kuperwasser B et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: results of a randomized, double-blind, placebo-and activecontrolled phase 3 study. Clinical Drug Invest 2010; 30: 489-505.
39. Buynak R, Shapiro DY, Okamoto A et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled phase III study. Expert Opin Pharmacother 2010; 11: 1787-804.
40. Basilisco G, Camboni G, Bozzani A et al. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci 1987; 32: 829-832. (Pubitemid 17135284)
41. Kaufman PN, Krevsky B, Malmud LS et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-1356.
42. Meissner W, Schmidt U, Hartmann M et al. Oral naloxone reverses opioidassociated constipation. Pain 2000; 84: 105-9.
43. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-144. (Pubitemid 26110994)
44. Vondrackova D, Leyendecker P, Meissner W et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-1154.
45. Meissner W, Leyendecker P, Mueller-Lissner S et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 56-64.
46. Sandner-Kiesling A, Leyendecker P, Hopp M et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 763-774.
47. Webster LR, Brewer R, Wang C et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010; 40: 734-746.
48. Foss JF. A review of the potential role of methyl-naltrexone in opioid bowel dysfunction. Am J Surg 2001; 182 (5A Suppl): 19S-26S. (Pubitemid 34072943)
49. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007; 41: 984-993.
50. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283: 367-372. (Pubitemid 30051755)
51. Yuan CS, Foss JF, Osinski J et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997; 61: 467-475. (Pubitemid 27195949)
52. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996; 59: 469-475. (Pubitemid 26151630)
53. Yuan CS, Foss JF, O'Connor M et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 1999; 83: 631-5.
54. Yuan CS, Foss JF, O'Connor M et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000; 67: 398-404. (Pubitemid 30246817)
55. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358: 2332-2343. (Pubitemid 351749157)
56. Lang L. The food and drug administration approves methylnaltrexone bromide for opioid-induced constipation. Gastroenterology 2008; 135: 6. (Pubitemid 351899040)
57. http://www.thomsonhc.com/hcs/librarian/MICROMEDEX: Physician's Desk Reference: methylnaltrexone.
58. Wong BS, Rao AS, Camilleri M et al. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther 2010; 32: 884-893.
59. Schmidt WK. Alvimopan (ADL 8-298) is a novel peripheral opioid antagonist. Am J Surg 2001; 182: 27S-38S. (Pubitemid 34072944)
60. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005; 17: 157-165. (Pubitemid 40476675)
61. http://www.thomsonhc.com/hcs/librarian/MICROEDEX: Physician's Desk Reference: Alvimopan.
62. Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184-192. (Pubitemid 40365022)
63. Webster L, Jansen JP, Peppin J et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioidinduced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008; 137: 428-440.
64. Gonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784-791. (Pubitemid 41116731)
65. Eldon MA, Song D, Neumann TA et al. Oral NKTR-118 (oral PEGnaloxol), a PEGylated derivative of naloxone; demonstration of selective peripheral opioid antagonism aft er oral administration in preclinical models. American Academy of Pain Management 18th Annual Clinical Mtg., Las Vegas, NV, 27-30 September 2007, poster 28.
66. Odinecs A, Gadiraju R, Sisco J et al. Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug. J Clin Pharmacol 2009; 49: 1123 (abstract).
67. Neumann TA, van Paaschen H, Marcantonio A et al. Clinical investigation of oral NKTR-118 as a selective oral peripheral opioid antagonist. 18th Annual Clinical Mtg. of the American Academy of Pain Management, Las Vegas, NV, Sept. 27-30, 2007, abstract 27.
68. McNicol E, Boyce DB, Schumann R et al. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med 2008; 9: 634-659.
69. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007; 34: 547-565. (Pubitemid 350001379)
70. Fei G, Raehal K, Liu S et al. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther 2010; 334: 333-340.
71. Cryer BL, Katz S, Vallejo R et al. A Phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioidinduced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010; 138 (Suppl 1): S-129.
72. Afilalo M, Etropolski MS, Kuperwasser B et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: results of a randomized, double-blind, placebo-and active controlled phase 3 study. Clin Drug Invest 2010; 30: 489-505.
73. Slappendel R, Simpson K, Dubois D et al. Development of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006; 10: 209-217. (Pubitemid 43255207)
74. Sloots CE, Rykx A, Cools M et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010; 55: 2912-2921.
75. Rentz AM, Yu R, Müller-Lissner S et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-383.
76. Camilleri M, Rothman M, Ho KF et al. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol 2011; 106: 497-506.